Please ensure Javascript is enabled for purposes of website accessibility

Multistate Operator Trulieve Cannabis Acquires Pennsylvania Dispensary Chain

By Eric Volkman - Apr 5, 2021 at 8:23PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

There aren't many dispensary licenses available in Pennsylvania; the company is about to grab one of them.

Multistate operator (MSO) Trulieve Cannabis (TCNNF -1.96%) is beefing up its presence in Pennsylvania. The company announced Monday that it has reached an agreement to purchase a dispensary license from Anna Holdings, under which it is permitted to operate three pot retail stores branded Keystone Shops in the state.

Trulieve will hand over an up-front payment of $60 million for the license, $40 million of which consists of its subordinate voting shares, with the remainder in cash. The company said it expects the acquisition to close by the end of the second quarter. It is subject to approval from the relevant regulatory authorities.

Generic marijuana dispensary sign.

Image source: Getty Images.

With the three new stores, Trulieve's count will increase to 86. The three Keystone Shops outlets are located in Philadelphia -- the state's most populous city -- Devon, and King of Prussia.

Already strong in its home state of Florida, Trulieve has lately been concentrating resources on enlarging its footprint elsewhere. The company's CEO Kim Rivers was quoted as saying that her company "continues to bolster our national expansion efforts with acquisitions that both complement our current portfolio and strengthen our long-term strategy."

Since Anna Holdings is a privately held company and does not publish its financials, we don't have a fix on how much revenue the three dispensaries take in. Regardless, they are located in fairly populous areas (particularly the Philadelphia store), and the fact that Pennsylvania limits its dispensary licensing makes them that much more valuable. So this feels like a sensible and opportunistic buy for Trulieve.

Investors might be concerned about the price tag of the deal, though. On Monday, Trulieve stock closed 0.3% lower, in contrast to the 1.4% gain of the S&P 500 index.

 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Trulieve Cannabis Stock Quote
Trulieve Cannabis
TCNNF
$14.48 (-1.96%) $0.29

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
345%
 
S&P 500 Returns
119%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/16/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.